Cefuroxime sodium - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for cefuroxime sodium and what is the scope of freedom to operate?
Cefuroxime sodium
is the generic ingredient in seven branded drugs marketed by B Braun, Acs Dobfar Spa, Fresenius Kabi Usa, Hikma, Hospira Inc, Teva Pharms, Watson Labs Inc, Samson Medcl, Acs Dobfar, Lilly, and Pai Holdings Pharm, and is included in twenty NDAs. Additional information is available in the individual branded drug profile pages.There are sixteen drug master file entries for cefuroxime sodium. Three suppliers are listed for this compound.
Summary for cefuroxime sodium
US Patents: | 0 |
Tradenames: | 7 |
Applicants: | 11 |
NDAs: | 20 |
Drug Master File Entries: | 16 |
Finished Product Suppliers / Packagers: | 3 |
Raw Ingredient (Bulk) Api Vendors: | 104 |
Clinical Trials: | 3 |
Patent Applications: | 1,382 |
What excipients (inactive ingredients) are in cefuroxime sodium? | cefuroxime sodium excipients list |
DailyMed Link: | cefuroxime sodium at DailyMed |
Recent Clinical Trials for cefuroxime sodium
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Hospital Universitari Vall d'Hebron Research Institute | Phase 4 |
University Hospital, Basel, Switzerland | Phase 4 |
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 2/Phase 3 |
Pharmacology for cefuroxime sodium
Drug Class | Cephalosporin Antibacterial |
Anatomical Therapeutic Chemical (ATC) Classes for cefuroxime sodium
US Patents and Regulatory Information for cefuroxime sodium
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Pai Holdings Pharm | ZINACEF | cefuroxime sodium | INJECTABLE;INTRAMUSCULAR, INTRAVENOUS | 050558-002 | Oct 19, 1983 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Watson Labs Inc | CEFUROXIME SODIUM | cefuroxime sodium | INJECTABLE;INJECTION | 064035-002 | Feb 26, 1993 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Pai Holdings Pharm | ZINACEF IN PLASTIC CONTAINER | cefuroxime sodium | INJECTABLE;INJECTION | 050643-001 | Apr 28, 1989 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Teva Pharms | CEFUROXIME SODIUM | cefuroxime sodium | INJECTABLE;INJECTION | 064191-001 | Apr 16, 1998 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Samson Medcl | CEFUROXIME SODIUM IN PLASTIC CONTAINER | cefuroxime sodium | INJECTABLE;INJECTION | 065251-001 | Dec 30, 2009 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Samson Medcl | CEFUROXIME SODIUM IN PLASTIC CONTAINER | cefuroxime sodium | INJECTABLE;INJECTION | 065251-002 | Dec 30, 2009 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.